Skip to main content

Table 1 Clinical characteristics at start of TNFi treatment and changes of outcome measures at follow-up visit (2–8 months) among RA patients overall, and stratified by ACPA status

From: A genetic risk score composed of rheumatoid arthritis risk alleles, HLA-DRB1 haplotypes, and response to TNFi therapy – results from a Swedish cohort study

Characteristic

Overall RA

ACPA-positive RA

ACPA-negative RA

Number of observations

867

653

165

Age, mean

51.2

51.3

51.5

Female (%)

74.1

72.1

79.2

Baseline values, mean

 DAS28

5.0

5.0

5.0

 CRP

21.0

21.9

19.1

 ESR

27.9

29

24.2

 SJC

7.8

7.8

8.1

 TJC

7.8

7.5

8.9

 VAS global health

54.1

53.8

54.5

 VAS pain

53.5

53.4

53.5

 HAQ

1.0

1.0

1.0

Changes from baseline to follow-up visit, mean

 ΔDAS28

–1.5

–1.5

–1.6

 ΔCRP

–10.2

–10.4

–9.3

 ΔESR

–9.2

–9.5

–8.2

 ΔSJC

–4.9

–4.8

–5.3

 ΔTJC

–4.3

–4.1

–4.9

 ΔVAS global health

–21.1

–21.7

–19.2

 ΔVAS pain

–21.6

–22.3

–19.7

 ΔHAQ

–0.3

–0.3

–0.3

EULAR response (%)

 No

25.2

25.6

23.6

 Moderate

31.4

30.6

33.1

 Good

43.4

43.8

43.3

  1. ACPA anti-citrullinated protein/peptide antibodies, DAS28 disease activity score 28, CRP C-reactive protein, ESR erythrocyte sedimentation rate, RA rheumatoid arthritis, SJC swollen joint count, TJC tender joint count, TNFi tumor necrosis factor inhibitor, VAS visual analog scale, HAQ Health Assessment Questionnaire, EULAR European League Against Rheumatism